EFFICACY OF LAETRILE IN TREATMENT OF CANCER PATIENTS WITH CHEMORADIATION ORAL MUCOSITIS

Background: Post-chemoradiation mucositis is a common and serious side effect that occurs in patients undergoing
cancer treatment. It is an inflammatory condition of the mucous membrane that can cause significant discomfort, pain, and a significant reduction in quality of life. Among the many methods used to relieve and treat mucositis, the drug Laetrile has attracted particular attention due to its potential therapeutic properties.
The aim of this study was to evaluate the effectiveness of Laetrile in treating post-chemoradiation mucositis.
Materials and Methods;The study involved 89 patients diagnosed with cancer of the oral mucosa (C00-C06, C10,
C13, C14 according to ICD-10) stages II and III (T2-3, N0-1, M0), aged 55 to 67 years, who received chemoradiation
therapy to the head and neck area. Depending on the treatment method, patients were divided into two groups:
comparison traditional treatment) and the main (developed method that reduced the incidence of bleeding gums,
erosions and ulcers of the oral mucosa.
Results: The use of Laetrile allowed to achieve a therapeutic-prophylactic effect in 55 (93.2%) of 89 patients treated
with Laetrile while in the comparison group (traditional treatment) in 19 (63.3%) of 30 patients
Conclusion: Laetrile is an interesting alternative in the treatment of postchemoradiation mucositis thanks to its
potential ability to reduce inflammation and promote tissue regeneration. Thus, although Laetrile is a promising option for managing the symptoms of mucositis, its potential benefits and risks have yet to be clarified in further research.